News summary

Lecanemab five-year data show slower decline than natural history cohorts

Source: Longevity Docs News • Published: 20 Nov 2026, 00:00

Summarized by Masters of Longevity from Longevity Docs News.

Open-label extension patients declined 2.05 CDR-SB points less than matched controls.

Lecanemab five-year data show slower decline than natural history cohorts
Key Takeaways
  • Treated early Alzheimer’s patients showed 2.05 point less decline.
  • The clinical gap continued to widen after 18 months.
  • Findings were from company-reported open-label comparison without controls.
Read the full article at Longevity Docs News ↗

Continue exploring

Recommended MoL Picks

MoL PickCreatine and Cancer: Why New Mouse Studies Point in Opposite DirectionsCreatine strengthened antitumour immune cells in one mouse study—and promoted metastasis through platelets in another. The apparent contradiction reveals why neither result is a supplement recommendation.MoL PickWhat Changes in the Human Hippocampus with Age?A study of 40 postmortem brains maps a midlife shift in immune cells and a wider loss of cellular and genome organisation—but it does not show how to prevent cognitive decline.MoL PickNucleotides and Longevity: Is the Evidence Ready?They help build DNA and keep cells working. Early human studies make nucleotide supplements interesting—but leave important questions about healthy ageing unanswered. Yet.